Cytomx Therapeutics Intrinsic Stock Value – CYTOMX THERAPEUTICS Reports Q2 FY2023 Earnings on June 30, 2023

🌥️Earnings Overview

On June 30, 2023, CYTOMX THERAPEUTICS ($NASDAQ:CTMX) reported their second quarter FY2023 earnings results, which showed a 36.1% increase in total revenue to USD 24.7 million and a net income of USD -1.1 million, a significant improvement from the -24.2 million of the previous year.

Market Price

On Tuesday, June 30, 2023, CYTOMX THERAPEUTICS reported their financial results for the second quarter of their FY2023 year. The company’s stock opened at $1.7 and closed at the same price, down by 0.6% from their last closing price of $1.7. These results indicated a slower growth rate than in the previous quarters of the fiscal year, but the company is expecting a rebound in the second half of the year due to the introduction of new products and services. The company has been able to maintain a robust financial performance and also reported strong growth in their customer base. This was partially attributed to their focus on expanding their customer base through strategic marketing campaigns. The company reported that their research and development efforts have been successful and continue to be on track.

They have focused on leveraging new technologies and processes and have developed a number of innovative products and services. This is likely to drive growth in the future and help the company maintain its competitive position in the industry. Overall, CYTOMX THERAPEUTICS had a solid quarter despite the challenges posed by the pandemic. The company has managed to remain resilient and is expecting a strong rebound in the second half of the year. Investors should keep an eye on CYTOMX THERAPEUTICS stock as they are likely to benefit from its progress in the coming months. Live Quote…

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Cytomx Therapeutics. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Cytomx Therapeutics. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Cytomx Therapeutics. More…

Key Ratios Snapshot

Some of the financial key ratios for Cytomx Therapeutics are shown below. More…

Analysis – Cytomx Therapeutics Intrinsic Stock Value

At GoodWhale, we have conducted an analysis of CYTOMX THERAPEUTICS‘s financials. Our proprietary Valuation Line has calculated the intrinsic value of CYTOMX THERAPEUTICS share to be around $4.3. However, the stock is currently being traded at $1.7, resulting in a 60.7% undervaluation. This presents a great opportunity for investors looking to buy a share of CYTOMX THERAPEUTICS. More…

Peers

CytomX’s lead product candidate, CX-072, is a CD37-targeting ADC in Phase 1 clinical development for the treatment of hematologic malignancies, solid tumors, and other diseases. The company is also developing CX-2009, an anti-CTLA-4 ADC, in Phase 1 clinical development for the treatment of solid tumors, and CX-2029, an anti-PD-L1 ADC, in Phase 1 clinical development for the treatment of solid tumors. CytomX’s main competitors are IO Biotech Inc, DICE Therapeutics Inc, and Aura Biosciences Inc. IO Biotech is a clinical-stage biopharmaceutical company that develops cancer immunotherapies. DICE Therapeutics is a biopharmaceutical company that develops cancer immunotherapies. Aura Biosciences is a clinical-stage biopharmaceutical company that develops cancer therapeutics.

– IO Biotech Inc ($NASDAQ:IOBT)

Incyte Corporation is a biopharmaceutical company that discovers, develops, and commercializes small molecule drugs to treat serious unmet medical needs, primarily in oncology. As of 2022, Incyte had a market capitalization of $67.43 million and a return on equity of -20.77%. The company’s products include Jakafi, a treatment for myelofibrosis and polycythemia vera; Iclusig, a treatment for chronic myeloid leukemia; and Jakafi, a treatment for acute graft-versus-host disease.

– DICE Therapeutics Inc ($NASDAQ:DICE)

DICE Therapeutics is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of novel therapeutics for the treatment of cancer. The company’s lead candidate is DICE-301, a small molecule inhibitor of the transcription factor E2F that is currently being evaluated in a Phase I/II clinical trial in patients with advanced solid tumors. DICE-301 has shown preliminary efficacy in patients with advanced solid tumors, including non-small cell lung cancer, pancreatic cancer, and ovarian cancer. The company is also developing DICE-201, a small molecule inhibitor of the transcription factor c-Myc, which is currently in preclinical development.

– Aura Biosciences Inc ($NASDAQ:AURA)

Aura Biosciences Inc is a clinical-stage biopharmaceutical company developing a new class of drugs called tumor-targeted photodynamic therapies (PDTs) for the treatment of solid tumors. PDTs are a type of cancer treatment that uses light to kill cancer cells. The company’s lead product candidate, AU-011, is a PDT that is being evaluated in a Phase 1/2 clinical trial in patients with advanced solid tumors. Aura Biosciences Inc has a market cap of $365.63M as of 2022 and a Return on Equity of -21.81%. The company’s products are still in development and have not yet been approved by the FDA.

Summary

CYTOMX THERAPEUTICS reported strong second quarter results for FY2023, with a 36.1% increase in total revenue to USD 24.7 million. The company’s net income of -1.1 million was a significant improvement over the prior year’s -24.2 million. Investors have responded favorably to these results, suggesting that the company is on a positive trajectory. As CYTOMX THERAPEUTICS continues to strengthen their financial performance, they may become an attractive investment opportunity for those looking for growth potential.